0
The Orthopaedic Forum   |    
Molecular Biology and Therapeutics in Musculoskeletal Oncology*
Theresa A. Guise, MD1; Regis O'Keefe, MD, PhD2; R. Lor Randall, MD3; Richard M. Terek, MD4
1 University of Virginia Health System, P.O. Box 801419, Charlottesville, VA 22908
2 University of Rochester, 601 Elmwood Avenue, Box 665, Rochester, NY 14642
3 University of Utah, Salt Lake City, UT
4 Brown University, 2 Dudley Street, Suite 200, Providence, RI 02905. E-mail address: Richard_Terek@Brown.edu
View Disclosures and Other Information
This report is a summary of the Molecular Biology and Therapeutics in Musculoskeletal Oncology Research Symposium sponsored by the American Academy of Orthopaedic Surgeons and the Orthopaedic Research Society, Salt Lake City, Utah, September 25, 26, and 27, 2008.
Disclosure: In support of their research for or preparation of this work, one or more of the authors received, in any one year, outside funding or grants in excess of $10,000 from National Institutes of Health R-13 Meeting Support Grant and less than $10,000 from the Musculoskeletal Transplant Foundation. Other funding was directed to the American Academy of Orthopaedic Surgeons (Orthopaedic Research Society, Orthopaedic Research and Education Foundation, Musculoskeletal Tumor Society, WWWW Foundation, Stryker, Biomet, and Musculoskeletal Transplant Foundation). Neither they nor a member of their immediate families received payments or other benefits or a commitment or agreement to provide such benefits from a commercial entity.

The Journal of Bone and Joint Surgery, Inc.
J Bone Joint Surg Am, 2009 Mar 01;91(3):724-732. doi: 10.2106/JBJS.I.00012
5 Recommendations (Recommend) | 3 Comments | Saved by 3 Users Save Case

Extract

Musculoskeletal oncology encompasses a broad array of diseases and treatment challenges. The most important issue facing a patient with a sarcoma is cure. Traditional cytotoxic chemotherapy has evolved empirically over the last several decades. While substantial improvements have been made in cure rates for pediatric patients with sarcoma, cure rates have plateaued at considerably less than 100% and chemotherapy for adult patients is far less effective. Starting with cytogenetic analysis and, more recently, the molecular dissection of tumors, it has become obvious that "sarcoma" is not a diagnosis per se but a group of diseases. Adult soft-tissue sarcoma alone comprises many different histologic subtypes. A better understanding of the biology of tumors at the molecular level has brought forth the possibility of targeted therapy, prompting the American Academy of Orthopaedic Surgeons (AAOS) and the Orthopaedic Research Society (ORS) to hold the Molecular Biology and Therapeutics in Musculoskeletal Oncology Research Symposium in September 2008.
Figures in this Article

    First Page Preview

    View Large
    />
    First page PDF preview
    Sign In to Your Personal ProfileSign In To Access Full Content
    Not a Subscriber?
    Get online access for 30 days for $35
    New to JBJS?
    Sign up for a full subscription to both the print and online editions
    Register for a FREE limited account to get full access to all CME activities, to comment on public articles, or to sign up for alerts.
    Register for a FREE limited account to get full access to all CME activities
    Have a subscription to the print edition?
    Current subscribers to The Journal of Bone & Joint Surgery in either the print or quarterly DVD formats receive free online access to JBJS.org.
    Forgot your password?
    Enter your username and email address. We'll send you a reminder to the email address on record.

     
    Forgot your username or need assistance? Please contact customer service at subs@jbjs.org. If your access is provided
    by your institution, please contact you librarian or administrator for username and password information. Institutional
    administrators, to reset your institution's master username or password, please contact subs@jbjs.org

    References

    Accreditation Statement
    These activities have been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the American Academy of Orthopaedic Surgeons and The Journal of Bone and Joint Surgery, Inc. The American Academy of Orthopaedic Surgeons is accredited by the ACCME to provide continuing medical education for physicians.
    CME Activities Associated with This Article
    Submit a Comment
    Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
    Comments are moderated and will appear on the site at the discretion of JBJS editorial staff.

    * = Required Field
    (if multiple authors, separate names by comma)
    Example: John Doe





    Related Content
    The Journal of Bone & Joint Surgery
    JBJS Case Connector
    Topic Collections
    Related Audio and Videos
    PubMed Articles
    Clinical Trials
    Readers of This Also Read...
    JBJS Jobs
    11/15/2013
    LA - Ochsner Health System
    03/05/2014
    OK - The University of Oklahoma
    04/02/2014
    WV - Charleston Area Medical Center
    10/12/2011
    NY - Modern Chiropractic Care, P.C.